Health and Fitness Health and Fitness
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti
[ Tue, Dec 13th 2011 ] - Market Wire
Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. uestcor Pharmaceuticals, Inc. and Perrigo Company
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. ceutical Industries Ltd (ADR) and Sanofi SA (ADR)
[ Tue, Dec 13th 2011 ] - Market Wire
A Change in Tides - Featured Research on Tenet Healthcare Corporation and Deluxe Corporation
[ Tue, Dec 13th 2011 ] - Market Wire
A Potent and Safe Wound Care Agent
[ Tue, Dec 13th 2011 ] - Market Wire
GenVec President and Chief Executive Officer Announces Retirement
[ Tue, Dec 13th 2011 ] - Market Wire
Keryx Biopharmaceuticals Announces Phase 2 Data f .. e) in Hodgkin's Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
New Clinical Study Presented at the NYPGA Meeting .. oring -- Considered the Fourth Primary Vital Sign
[ Tue, Dec 13th 2011 ] - Market Wire
China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder
[ Tue, Dec 13th 2011 ] - Market Wire
Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Baxter Signs Definitive Agreement to Acquire Synovis
[ Tue, Dec 13th 2011 ] - Market Wire
St. Jude Medical Board of Directors Authorizes Share Repurchase and Fourth Quarter Dividend
[ Tue, Dec 13th 2011 ] - Market Wire
SANUWAVE Technology Shown to Proliferate Adult Stem Cells
[ Tue, Dec 13th 2011 ] - Market Wire
Cubist Announces First Patient Dosed in Pivotal G .. XA-201 for Complicated Intra-Abdominal Infections
[ Tue, Dec 13th 2011 ] - Market Wire
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II evala la ventaja clnica de pom .. con mieloma mltiple con pretratamiento intensivo
[ Tue, Dec 13th 2011 ] - Market Wire
Fase 2-onderzoek evalueert klinisch profijt van p .. j eerder behandelde patinten met multipel myeloom
[ Tue, Dec 13th 2011 ] - Market Wire
Endgltige Daten aus multizentrischer Phase-II-Stu .. binationstherapie von VIDAZA und REVLIMID fr MDS-
[ Tue, Dec 13th 2011 ] - Market Wire
Presentados en ASH los datos finales de un estudi .. evala la combinacin de VIDAZA y REVLIMID en pacie
[ Tue, Dec 13th 2011 ] - Market Wire
Phase-II-Studie von ISTODAX bei Patienten mit rez .. peripheres T-Zell-Lymphom): Prsentation der Teila
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II de ISTODAX en pacientes con li .. (PTCL) recurrente o resistente: presentado en ASH
[ Tue, Dec 13th 2011 ] - Market Wire
Fase II onderzoek van ISTODAX bij patinten met re .. len perifeer t-cel lymfoom (PTCL): subanalyse van
[ Tue, Dec 13th 2011 ] - Market Wire
Nektar Announces Positive Clinical Data from Seco .. NKTR-181, a Novel Opioid Analgesic Molecule to Tr
[ Tue, Dec 13th 2011 ] - Market Wire
Aethlon Medical Announces HIV-AIDS Research Discovery
[ Tue, Dec 13th 2011 ] - Market Wire
Stem Cell Therapeutics Announces Additions to Advisory Board
[ Tue, Dec 13th 2011 ] - Market Wire
Eindgegevens van Fase II multi-center onderzoek n .. REVLIMID bij patinten met hoogrisico MDS gepresen
[ Tue, Dec 13th 2011 ] - Market Wire
UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema
[ Tue, Dec 13th 2011 ] - Market Wire
BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase III sobre terapia continuada con .. stadsticamente significativas en la supervivencia

Estudio de Fase III sobre terapia continuada con REVLIMID demuestra mejoras estadsticamente significativas en la supervivencia


Published on 2011-12-13 03:22:54 - Market Wire
  Print publication without navigation


BOUDRY, Suiza--([ ])--Celgene International Srl, filial de Celgene Corporation (NASDAQ: CELG), ha anunciado que los datos del anlisis provisional previsto de MM-015, un estudio de fase III, aleatorio, con doble anonimato de la terapia continua de REVLIMID (lenalidomida) para el tratamiento de pacientes con mieloma mltiple de nuevo diagnstico que no eran aptos para un transplante de clulas madre, registraron una mejora clnicamente significativa en la supervivencia sin progresin, el principal criterio de evaluacin del estudio.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources